collaboration
Personalis, Tempus Partner to Commercialize Blood-Based Minimal Residual Disease Test
Tempus will market Personalis' NeXT Personal Dx liquid biopsy while Personalis completes its clinical validation in more indications.
GenDx, OSE Immunotherapeutics Ink Deal to Develop NGS CDx for Epitope-Based Cancer Vaccine
Under the deal, GenDx will develop and validate a companion diagnostic test for high-resolution typing of HLA-A*02 based on its IVDR-registered NGS products.
UK Nonprofits Launch Childhood Cancer Research Program to Advance Precision Medicine
Children With Cancer UK and Cancer Research UK are providing £5.5 million to advance liquid biopsy tests to match patients to drugs and advance new therapies.
Alimentiv, AcelaBio, PharmaNest Partner to Find New NASH/MASH Biomarkers
The collaboration aims to help clinical trial sponsors understand drug effects and disease biology through spatial biology-based analyses.
Jazz Pharmaceuticals, MD Anderson Partner on Zanidatamab Studies in HER2-Expressing Cancers
The partners will jointly form a steering committee and fund multiple trials evaluating the HER2-targeting agent over five years.